September 25, 2020
Ohara Pharmaceutical on September 24 filed a new drug application for its chimeric monoclonal antibody dinutuximab for the treatment of neuroblastoma in Japan. The company licensed the drug from US biotech United Therapeutics in 2012. The submission is based on...read more